Studied in the lab. Proven in humans.
Clinical research is a core differentiator between Elysium and everyone else. We study our products in humans so you can take proactive steps to support your health — and be confident that your decisions are based on scientific evidence.
Our current pipeline includes preclinical and clinical trials for skin, microbiome, muscle, cognition, and circadian rhythm.
Beyond Basis, Elysium is working with its scientific advisors and university partners to identify other natural compounds that improve healthspan. Our R&D process begins by identifying promising new research and natural compounds that support healthspan and a comprehensive evaluation of all available scientific literature. These compounds are all tested for safety and efficacy in placebo-controlled human trials before coming to market.
As you can see from our current research pipeline (pictured below), there’s a lot happening behind the scenes at Elysium — and a lot to look forward to.
Our First Clinical Trial
Basis Increases NAD+ Levels, Safely and Sustainably
Our double-blind, randomized, placebo-controlled clinical trial, published in November 2017 in the peer-reviewed journal Nature Partner Journals: Aging and Mechanisms of Disease, demonstrated that Basis is proven to increase NAD+ levels by an average of 40 percent in adults taking the recommended daily dose.